| Product Descriptions | ||||||
|---|---|---|---|---|---|---|
| Product | Cas | Purity | Molecular Formula | Physical State | End Use | Structure |
| (R)-tetrahydrofuran-3-yl 4-methylbenzenesulfonate | 219823-47-9 | 97% | C11H14O4S | Solid | Empagliflozin |  |
| (4R,12AS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methy | 1335210-35-9 | 97% | C21H21F2N3O5 | Liquid | Dolutegravir |  |
| 1-(2,2-Dimethoxyethyl)-5-methoxy-6-(methoxycarbony | 1335210-23-5 | 98% | C13H17NO8 | Liquid | Dolutegravir |  |
| Methyl 3-(benzyloxy)-1-(2,3-dihydroxypropyl)-4-oxo | 1206102-07-9 | 97% | C17H19NO6 | Liquid | Dolutegravir |  |
| 6,7-Dimethoxyquinazoline-2,4-dione | 28888-44-0 | 97% | C10H10N2O4 | Solid | Prazosin |  |
| 1-(2-Furoyl)piperazine | 40172-95-0 | 97% | C9H12N2O2 | Solid | Prazosin |  |
| (R)-N-(2-(4-isopropyl-4,5-dihydrooxazol-2-yl) – | 871360-40-6 | 98% | C14H20N2O3S | Liquid | Erubilin |  |
| 1-bromovinyl) trimethylsilane | 13683-41-5 | 98% | C5H11BrSi | Solid | Erubilin |  |
| (R)-tert-butyldimethyl(3-(oxiran-2-yl)propoxy)sila | 197229-73-5 | 95% | C11H24O2Si | Liquid | Erubilin |  |
| N-[2-[(4S)-4,5-Dihydro-4-(1-methylethyl)-2-oxazoly | 480444-15-3 | 95% | C14H20N2O3S | Solid | Erubilin |  |
| 6,7-BIS(2-METHOXYETHOXY)QUINAZOLIN-4(1H)-ONE | 179688-29-0 | 98% | C14H18N2O5 | Liquid | Erlotinib |  |
| 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline | 183322-18-1 | 98% | C14H17ClN2O4 | Liquid | Erlotinib |  |
| Benzofuran-6-carboxylic acid | 77095-51-3 | 98% | C9H6O3 | Liquid | Lifitegrast |  |
| 6-Isoquinolinecarboxylic Acid, 5,7-dichloro-1,2,3, | 1289646-93-0 | 97% | C10H10Cl3NO2 | Solid | Lifitegrast |  |
| (S)-2-Amino-3-(3-(Methylsulfonyl)Phenyl)Propanoic | 1270093-99-6 | 98+% | C10H13NO4S | Solid | Lifitegrast |  |
| 2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde | 29668-44-8 | 98% | C9H8O3 | Liquid | Eliglustat |  |
| 4'-(Aminomethyl)biphenyl-2-Carbonitrile | 133690-92-3 | 97% | C14H12N2 | Solid | Irbesartan |  |
| 4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-y | 138401-24-8 | 95+% | C25H27N3O | Liquid | Irbesartan |  |
| 2-n-Butyl-1,3-diazaspiro[4.4]non-1-en-4-one | 138402-05-8 | 95% | C11H18N2O | Liquid | Irbesartan |  |
| 4-Bromomethyl-2-cyanobiphenyl | 114772-54-2 | 95% | C14H10BrN | Liquid | Irbesartan |  |
| 9-(4'-chloro-[1,1'-biphenyl]-3-yl)-9H-carbazole | 2148296-04-0 | 98+% | C24H16ClN | Solid | OLED Intermediates |  |
| 9-(4'-chloro-[1,1'-biphenyl]-2-yl)-9H-carbazole | 2098811-14-2 | 98% | C24H16ClN | Solid | OLED Intermediates |  |
| 4-Amino-2-fluoro-N-methylbenzamide | 915087-25-1 | 98% | C8H9FN2O | Liquid | OLED Intermediates |  |
| (3R)-Tetrahydrofuran-3-yl 4-Methylbenzenesulfonate | 219823-47-9 | 97% | C11H14O4S | Solid | APALUTAMIDE | |
| 4-bromo-1-chloro-2-(4-methoxybenzyl)benzene | 333361-51-6 | 97% | C14H12BrClO | Solid | Empagliflozin |  |
| Ethylene glycol chlorophosphate, | 6609-64-9 | 95% | C2H4ClO3P | liquid | Empagliflozin |  |
| (R)-(+)-2-[2-(Diphenylphosphino)phenyl]-4-(1-methy | 164858-78-0 | 97.0% | C24H24NOP | powder | Empagliflozin |  |
| Methyl-2-Furoate | 611-13-2 | 98% | C6H6O3 | liquid | Lificiguat |  |
| 4-Hydroxy-2-methyl-pyrimidine-5-carboxylic acid et | 53135-24-3 | 95% | C8H10N2O3 | Liquid | Lificiguat |  |
| N-(DIPHENYLMETHYLENE) GLYCINE ETHYL ESTER | 69555-14-2 | 95% | C17H17NO2 | Liquid | Thiamine hydrochloride |  |
| Ethyl 2-amino-3-cyclobutylpropanoate hcl | 565456-74-8 | 95% | C9H18ClNO2 | Solid | Boceprevir |  |
| 6,6-DiMethyl-3-azabicyclo[3.1.0]hexane | 943516-54-9 | 97% | C7H13N | Liquid | Boceprevir | .png) |
| N-(DIPHENYLMETHYLENE) GLYCINE ETHYL ESTER | 69555-14-2 | 95% | C17H17NO2 | Liquid | Omarigliptin | |
| 4-[(2-Cyanopropan-2-yl)amino]-2-fluoro-N-methylben | 915087-32-0 | 97% | C12H14FN3O | Solid | EnzalutaMide |  |
| N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-met | 1289942-66-0 | 97% | C12H15FN2O3 | Liquid | EnzalutaMide |  |
| N-[(S)-(+)-1-(Ethoxycarbonyl)-3-phenylpropyl]-L-al | 82717-96-2 | 98% | C6H5CH2CH2CH(CO2C2H5)NHCH(CH3)CO2H | Solid | EnzalutaMide |  |
| 1-Hydroxybenzotriazole | 2592-95-2 | 5% in H2O | C6H5N3O | Solid | Ramipril & Enalapril Maleate |  |
| 1-Benzyl-4-piperidinecarboxaldehyde | 22065-85-6 | 95% | C13H17NO | Liquid | Levetiracetam |  |
| 2-Bromo-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethan | 62932-94-9 | 95% | C₉H₉BrO₃ | solid | Itraconazole |  |
| 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole Hydro | 84163-13-3 | 98% | C12H14ClFN2O | Solid | Salmeterol Xinafoate |  |
| AMINO DIPHENYL METHANOL | 1426129-50-1 | 95% | C20H25NO3 | Solid | Sacubitril |  |
| Ethyl 2-(Triphenylphosphoranylidene)propionate | 5717-37-3 | 94% | CH3C[=P(C6H5)3]CO2C2H5 | Solid | Sacubitril |  |
| 1,2,6,7-tetrahydroindeno[5,4-b]furan-8-one, 1,2,6, | 196597-78-1 | 97% | C11H10O2 | Liquid | Ramelteon |  |
| 4,5-Dibromo-1,2,6,7-tertahydro-8H-indeno[5,4-b]fur | 196597-77-0 | 97+% | C11H8Br2O2 | Solid | Ramelteon |  |
| (S)-2-(1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8- | 196597-81-6 | 95+% | C13H17NO | Liquid | Ramelteon |  |
| 2,3-Dihydro-4-benzofurancarboxaldehyde | 209256-42-8 | 95% | C9H8O2 | Liquid | Tasimelteon |  |
| 4-Vinyl-2,3-dihydrobenzofuran | 230642-84-9 | 95% | C10H10O | Liquid | Tasimelteon |  |
| 1-Benzofuran-4-carbaldehyde | 95333-13-4 | 97% | C9H6O2 | Solid | Tasimelteon |  |
| Triethylenetetramine | 112-24-3 | 97.0% | NH2CH2CH2(NHCH2CH2)2NH2 | liquid | Trientine |  |
| 4-(2-Bromoethyl)-1,3-dihydro-2H-indolin-2-one | 120427-96-5 | 97% | C10H8BrNO | Liquid | Sacubitril Valsartan |  |
| (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo | 168828-90-8 | 98% | C14H18FN3O3 | Liquid | Linezolid |  |
| (R)-3-(3-Fluoro-4-morpholinophenyl)-5-(hydroxymeth | 168828-82-8 | 98% | C14H17FN2O4 | Liquid | Linezolid |  |
| 3-Fluoro-4-morpholin-aniline | 93246-53-8 | 98% | C10H13FN2O | Liquid | Linezolid |  |
| 2-Bromomethyl-3-nitrobenzoic acid methyl ester | 98475-07-1 | 95% | C9H8BrNO4 | Liquid | Lenalidomide |  |
| 3-(4-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)piperidi | 827026-45-9 | 97% | C13H11N3O5 | Liquid | Lenalidomide |  |
| (1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-1-[(3S)-3- | 101692-02-8 | 97% | C21H32O3 | Solid | Treprostinil |  |
| 2-[[(1S)-1-(3-Butynyl)hexyl]oxy]tetrahydro-2H-pyra | 223734-62-1 | 95% | C15H26O2 | Solid | Treprostinil |  |
| (R)-(+)-alpha,alpha-Diphenyl-2-pyrrolidinemethanol | 22348-32-9 | 98% | C17H19NO | solid | Treprostinil |  |
| (R)-2-Methyl-CBS-oxazaborolidine | 112022-83-0 | 90% | C18H20BNO | solid | Treprostinil |  |
| 1-(Trimethylsilyl)propyne, | 6224-91-5 | 99% | CH3C≡CSi(CH3)3 | liquid | Treprostinil |  |
| 2-Phenylacetophenone | 451-40-1 | 97% | C6H5COCH2C6H5 | crystals | Valdecoxib |  |
| 5-methyl-3,4-diphenyl-4H-1,2-oxazol-5-ol | 181696-73-1 | 98% | C16H15NO2 | Liquid | Valdecoxib |  |
| (2b,3a,5a,16b,17b)-2-(4-Morpholinyl)-16-(1-pyrroli | 119302-20-4 | N/A | C27H46N2O3 | Solid | Rocuronium Bromide |  |
| Diethyl Aminomalonate Hydrochloride | 13433-00-6 | 98% | C7H14ClNO4 | N/A | Rocuronium Bromide |  |
| Ethyl 4-(2-Hydroxy-2-Propyl)-2-Propyl-1H-Imidazole | 144689-93-0 | 97% | C12H20N2O3 | Liquid | OLMESARTAN |  |
| 3,5-Dichlorobenzoic acid | 51-36-5 | 97% | Cl2C6H3CO2H | powder | Tafamidis |  |
| 4-Amino-3-hydroxybenzoic acid | 2374-03-0 | 98% | C7H7NO3 | Liquid | Tafamidis |  |
| 3,6-Difluoropyrazine-2-carboxamide | 356783-29-4 | 95% | C5H3F2N3O | Solid | Favipiravir |  |
| 4-Amino-5-chloro-2,3-dihydrobenzofuran-7-carboxyli | 123654-26-2 | 97% | C9H8ClNO3 | Liquid | Prucalopride |  |
| Methyl-4-Acetylamino-3-Bromo5-Chloro-2-Hydroxy Ben | 232941-14-9 | 95% | C10H9BrClNO4 | Solid | Prucalopride |  |
| 4,6-dimethyl-2-hydroxynicotinonitrile | 769-28-8 | 97% | C8H8N2O | Solid | Opicapone |  |
| AMINO DIPHENYL METHANOL | 1426129-50-1 | 95% | C20H25NO3 | Solid | Sacubitril | |
| 1-CARBETHOXYETHYLIDENE TRIPHENYL PHOSPHR | 5717-37-3 | 97% | C23H23O2P | Liquid | Sacubitril |  |
| (2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl) | 1012341-50-2 | 95% | C23H29NO4 | Solid | Sacubitril |  |
| 3-hydroxyisobenzofuran-1(3H)-one | 16859-59-9 | 97% | C8H6O3 | Liquid | Olaparib |  |
| 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthal | 763111-47-3 | 97% | C20H19FN4O2 | Solid | Olaparib |  |
| 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)Meth | 763114-26-7 | 98% | C16H11FN2O3 | C16H11FN2O3 | Olaparib |  |
| Dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phos | 61260-15-9 | 98% | C10H11O5P | Liquid | Olaparib |  |
| (S)-(-)-9,10-Difluoro-2,3-dihydro-3-methyl-7-oxo-7 | 100986-89-8 | 97% | C13H9F2NO4 | Liquid | LEVOFLOXACIN HEMIHYDRATE |  |
| N-Methyl-o-phenylenediamine dihydrochloride | 25148-68-9 | 99% | C7H12Cl2N2 | Liquid | Telmisartan |  |
| Methyl 4-butyramido-3-methylbenzoate | 301533-59-5 | 97% | C13H17NO3 | Liquid | Telmisartan |  |
| Triethylenetetramine | 112-24-3 | 60.0% | C6H18N4 | Liquid | Trientine |  |
| 2,3-Diaminopyridine(2,3-DAP) | 452-58-4 | 97% | C5H7N3 | Liquid | Rimegepant |  |
| 1-Bromo-2,3-difluorobenzene | 38573-88-5 | 97% | C6H3BrF2 | Liquid | Rimegepant |  |
| 6,7-Diacetoxy-4-chloro-quinazoline | 938185-04-7 | 97% | C12H9ClN2O4 | Liquid | Icotinib |  |
| 4-Chloroquinazoline-6,7-diol | 1145671-36-8 | 95% | C8H5ClN2O2 | Solid | Icotinib |  |
| 6-Bromoacetyl-2,2-dimethyl-4H-benzo[1,3]dioxine | 102293-80-1 | 95% | C12H13BrO3 | Solid | Vilanterol |  |
| 2-[2-(6-Bromohexyloxy)ethoxymethyl]-1,3-dichlorobe | 503070-57-3 | 95% | C15H21BrCl2O2 | Liquid | Vilanterol |  |
| 2-Bromo-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethan | 62932-94-9 | 95+% | C9H9BrO3 | Solid | Vilanterol |  |
| 10-methoxy-5H-dibenzo[b,f]azepine | 4698--11-7 | 98.0% | C15H13NO | Solid | Oxcarbazepine |  |
| (1R,2R)-2-Amino-6-(4-nitrophenyl)-1-phenylhex-5-yn | 1628836-08-7 | 99% | C18H19ClN2O3 | Solid | Vibegron |  |
| Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate | 1458-01-1 | 98% | C6H7ClN4O2 | Solid | Amiloride hydrochloride |  |
| (2R,4S)-4-Amino-5-(biphenyl-4-yl)-2-methylpentanoi | 149690-12-0 | 95% | C20H26ClNO2 | Solid | Sacubitril |  |
| (S)-2-(3-((2-Isopropylthiazol-4-yl)methyl)-3-methy | 154212-61-0 | 95% | C14H23N3O3S | Liquid | Ritonavir |  |
| 4,4,4-Trifluoro-1-[4-(methyl)phenyl]-butane-1,3-di | 720-94-5 | 97% | C11H9F3O2 | Liquid | Celecoxib |  |
| 4-Hydrazinobenzenesulfonamide hydrochloride | 17852-52-7 | 97% | C6H10ClN3O2S | solid | Clopidogrel |  |
| Methyl(+)-alpha-amino(2-chlorophenyl)acetate tarta | 1233361-76-6 | 95% | C13H16ClNO8 | N/A | Clopidogrel |  |
| L-Glutamic acid diethyl ester hydrochloride | 1118-89-4 | 95% | C9H18ClNO4 | Solid | pemetrexed |  |
| 1-(4,5-Dinitro-10-aza-tricyclo[6.3.1.0]dodeca-2,4, | 230615-59-5 | 98% | C13H10F3N3O5 | Liquid | Varenicline |  |
| 3'-Amino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic a | 376592-93-7 | 98.0% | C13H11NO3 | Solid | Eltrombopag |  |
| 1-(3,4-Dimethylphenyl)hydrazine hydrochloride | 60481-51-8 | 97% | C8H13ClN2 | Liquid | Eltrombopag |  |
| 1-(3-Amino-5-trifluoromethylphenyl)-4-methylimidaz | 641571-11-1 | 98% | C11H10F3N3 | Liquid | Nilotinib |  |
| 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]b | 641569-94-0 | 97% | C17H14N4O2 | Liquid | Nilotinib |  |
| 3-Amino-3-iminopropanoic acid 1-(diphenylmethyl)-3 | 170749-59-4 | 98+% | C21H25N3O4 | Liquid | Azelnidipine |  |
| (3-Chloropyrazin-2-yl)MethanaMine hydrochloride | 939412-86-9 | 95% | C5H7Cl2N3 | Liquid | Acalabrutinib |  |
| (S)-Benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin | 1420478-88-1 | 97% | C18H18BrN5O2 | Liquid | Acalabrutinib |  |
| (4-(Pyridin-2-ylcarbamoyl)phenyl)boronic acid | 850568-25-1 | 97% | C12H11BN2O3 | Liquid | Acalabrutinib |  |
| 2-Butynoic acid | 590-93-2 | 98% | C4H4O2 | Liquid | Acalabrutinib |  |
| 3-Ethyl-4-methyl-2,5-dihydro-1H-pyrrol-2-one | 766-36-9 | 98.0% | C7H11NO | Solid | Glimepiride |  |
| 4-[2-[(3-Ethyl-4-methyl-2-oxo-3-pyrrolin-1-yl)carb | 119018-29-0 | 98% | C16H21N3O4S | Liquid | Glimepiride |  |
| 5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-on | 61718-80-7 | 98% | C13H15F3O2 | Liquid | Fluvoxamine maleate |  |
| 2,4,5-Trifluoro phenyl acetic acid | 209995-38-0 | 98% | C8H5F3O2 | solid | Sitagliptin |  |
| 3-(Trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]tria | 762240-92-6 | 98% | C₆H₈ClF₃N₄ | Solid | Sitagliptin |  |
| 2-[[(1S)-1-(3-Butynyl)hexyl]oxy]tetrahydro-2H-pyra | 223734-62-1 | 98% | C15H26O2 | Liquid | Treprostinil | |
| (1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-1-[(3S)-3- | 101692-02-8 | 98% | C21H32O3 | Solid | Treprostinil | |
| (R)-Tetrahydrofuran-3-yl 4-methylbenzenesulfonate | 219823-47-9 | 98% | C11H14O4S | White to Off-White Low-Melting Solid | Empagliflozin | |
